Cost-effectiveness analysis of toripalimab plus chemotherapy as the first-line treatment in patients with advanced non-small cell lung cancer (NSCLC) without EGFR or ALK driver mutations from the Chinese perspective
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 June 2023.
All research outputs
#15,579,818
of 23,923,788 outputs
Outputs from Frontiers in Pharmacology
#5,679
of 17,601 outputs
Outputs of similar age
#122,041
of 250,430 outputs
Outputs of similar age from Frontiers in Pharmacology
#89
of 572 outputs
Altmetric has tracked 23,923,788 research outputs across all sources so far. This one is in the 32nd percentile – i.e., 32% of other outputs scored the same or lower than it.
So far Altmetric has tracked 17,601 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.1. This one has gotten more attention than average, scoring higher than 61% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 250,430 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 48th percentile – i.e., 48% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 572 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 80% of its contemporaries.
